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Prime-boost vaccination with 
recombinant protein and 
adenovirus-vector expressing 
Plasmodium vivax circumsporozoite 
protein (CSP) partially protects 
mice against Pb/Pv sporozoite 
challenge
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Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. 
To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein 
(CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central 
repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-
AllFL) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct 
(yPvCSP-AllCT) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice 
were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used 
replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee 
serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in 
Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific 
to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or 
Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. 
These vaccine formulations should be clinically tried for their potential as protective universal vaccine 
against P. vivax malaria.
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Malaria is one of the most prevalent infectious diseases. It is caused by Plasmodium parasites that are transmitted 
through the bite of Anopheles mosquitoes in tropical regions. The discovery of alternative tools to control malaria 
is increasingly important because of the emergence of drug-resistant parasites and insecticide-resistant mosqui-
toes. In 2015, 214 million malaria cases and over 438,000 deaths occurred globally, indicating that the disease 
remains a significant public health concern1. In humans, malaria is caused by five species: Plasmodium falci-
parum, P. vivax, P. malariae, P. ovale, and P. knowlesi. Among the Plasmodium species, P. vivax is the most widely 
distributed worldwide and is most prevalent in the American continent. An increase in the number of cases with 
serious complications has been reported recently in several countries2; these complications include anaemia, res-
piratory distress syndrome, cerebral malaria, and malnutrition. In Brazil, 80% of malaria cases reported in 2015 
(about 143,000 infected people) were caused by P. vivax1.
According to the malERA (Malaria Eradication Research Agenda) consultative group, vaccination should 
control and, one day, even eliminate malaria. There is no approved vaccine against malaria thus far; however, 
some formulations are currently under clinical testing3. A malaria vaccine presently in late-phase clinical testing, 
RTS,S, manufactured by GlaxoSmithKline (GSK), is based on the P. falciparum circumsporozoite protein (PfCSP). 
RTS,S is a recombinant vaccine produced in Saccharomyces cerevisiae, which comprises the C-terminal portion of 
PfCSP, and repeat regions fused to the surface antigen (S) of hepatitis B virus4. This vaccine may contribute sub-
stantially to the control of malaria when used in combination with other control measures, especially in high-risk 
areas5. However, this vaccine targets only P. falciparum, as do almost all vaccine candidates tested so far3.
In contrast with PfCSP, P. vivax CSP has three allelic variants. This protein has B cell immunodominant 
epitopes consisting of repeats of core amino acids, and the two most common genotypic variants are VK210 
and VK2476–8. Each variant displays two main types of repetitions of nonapeptides: GDRA(D/A)GQPA and 
ANGA(G/A)(C/D)QPG, respectively8. A third variant of a human malaria parasite called “P. vivax-like” con-
taining the repeat APGANQ(E/G)GAA9,10 has been found in endemic regions of Papua New Guinea, as well 
as in Brazil, Indonesia, and Madagascar10. In Brazil, the prevalence of the three PvCSP allelic variants has been 
established11,12.
A subunit vaccine against P. vivax malaria is currently undergoing clinical testing. This vaccine, named 
VMP001, was expressed in Escherichia coli and encodes a chimeric CS protein containing repeat sequences of the 
two major alleles, VK210 and VK24710. Mice immunized with protein in Freund’s adjuvant produced antibodies 
(Abs) that recognize both VK210 and VK247 alleles and cause the agglutination of live sporozoites13. This pro-
tein was further tested in formulations with a Toll-like receptor (TLR)-9 agonist in Aotus nancymaae monkeys. 
Animals generated strong humoral immune responses, and protection was associated with Abs directed against 
the central regions of VK210 and VK24714. Results of the first Phase 1 trial with VMP001 showed that the vaccine 
was well tolerated and immunogenic, and all volunteers generated robust humoral and cellular responses to the 
vaccine antigen. Vaccination did not induce sterilizing protective immunity; however, a significant time delay for 
parasitemia was observed in 59% of vaccinated individuals compared to that seen in the control group15.
A strategy for improving the humoral response of protein-based subunit vaccines is to use adenoviral vec-
tors in heterologous prime-boost immunization regimens. Adenoviral vectors efficaciously induced long-lasting 
humoral and cellular immune responses in different models including malaria16–18. Moreover, these responses 
were associated with protection against Plasmodium infection in several studies16,19–22. Over the past decade, our 
group has generated and evaluated the immunogenicity of recombinant proteins and adenoviruses representing 
the three forms of P. vivax CSP. Recombinant proteins were initially expressed in Escherichia coli23–25 and their 
immunogenicities were tested by immunizing C57BL/6 mice with each protein in combination with Freund’s 
adjuvants (CFA/IFA) or the agonist of Toll-like receptor 3, Polyinosinic-polycytidylic acid [Poly (I:C)]. All recom-
binant proteins were highly immunogenic when administered either individually or together and specific Abs 
against all three allelic variants were obtained with either adjuvant, Freund’s or Poly (I:C). The Abs produced were 
directed against the CSP immunodominant domain repeats, N- and C-terminal regions25.
In this work, we used two chimeric proteins expressed as soluble products in Pichia pastoris. These recom-
binants merged the RI region with the three central repeat regions of different CSP alleles (VK210, VK247, 
and P. vivax-like), and also contained N- and C-terminal (yPvCSP-AllFL) or only C-terminal (yPvCSP-AllCT) 
regions from P. vivax CSP. In addition, we also used two adenoviral vectors (AdHu5 or AdC68) in heterologous 
prime-boost immunization regimens, and subsequently challenged immunized mice with transgenic P. vivax/P. 
berghei sporozoites (Pb/Pv).
Results
Two chimeric proteins based on PvCS were successfully produced in yeast. The final constructs 
of CSP used in this study have a repeat region that merges with the three variant repeat sequences reported until 
date: VK210, VK247, and P. vivax-like. The chimeric CSP in this study is composed of six repeats present in P. 
vivax VK210, six from P. vivax-like, and five from VK247. The structure of the final constructs of yPvCSP-AllFL 
and yPvCSP-AllCT are described in Fig. 1(a,b).
The protein yield was 3 mg/L of yPvCSP-AllFL and 8 mg/L of yPvCSP-AllCT. Both proteins were purified as 
described in the Methods section by affinity chromatography and ion exchange chromatography, and the final 
purity was >95% for yPvCSP-AllFL and yPvCSP-AllCT according to RP-HPLC. Both proteins had molecular 
weights of ~55 kDa under reducing conditions (Fig. 2a).
The electrophoresis analysis showed that yPvCSP-AllFL and yPvCSP-AllCT migrated without degradation 
products, and the proteins were recognised by specific monoclonal Ab anti-PvVK210 and mAb anti-PvVK24726 
(Fig. 2a,b). The results indicated that the introduction of limited copies of each PvCSP allelic variant was suffi-
cient for recognition by specific mAbs. In addition, the two recombinant proteins were detected by mAb anti-His, 
indicating His6-tag preservation (Fig. 2b).
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Reverse-phase chromatography on a C18 column, in which a single peak was observed, confirmed the high 
purity of the final yPvCSP-AllCT and yPvCSP-AllFL used in this study (Fig. 2c). To investigate the secondary 
structure, the recombinant proteins were examined by far-UV CD spectroscopy (Fig. 2d). The CD spectra were 
consistent with a structure comprising 2% α-helix, 43% β-sheet, and 55% β-turn for yPvCSP-AllCT, and 3% 
α-helix, 41% β-sheet, and 56% β-turn for yPvCSP-AllFL. The stability of the recombinant proteins following a 
freeze-drying process was also examined by SDS-PAGE (not shown). Both proteins preserved their conformation 
after the lyophilisation process.
Mice immunized with yPvCSP-AllFL or yPvCSP-AllCT generated high IgG titres specific to three 
allelic forms of PvCSP. C57BL/6 mice were immunized with 10 µg of each protein mixed with Poly (I:C) 
(50 µg/dose) adjuvant or emulsified in Montanide ISA720 (7:3). Regardless of which type of adjuvant was used, 
mice vaccinated individually with either yPvCSP-AllFL or yPvCSP-AllCT developed high IgG Ab titres (>105) spe-
cific to all CSP alleles after three doses (PPP). No difference was observed in the IgG titres specific to CSP (Fig. 3) 
with the three CSP alleles, indicating that recognition was similar. After immunization with the three doses of 
yPvCSP-AllFL/Montanide ISA720, mean IgG titres (log10 ± SEM) were 5.51 ± 0.12 to PvCSP-VK210, 5.56 ± 0.09 
to PvCSP-VK247, and 5.70 ± 0.12 to PvCSP-P. vivax-like. The formulation yPvCSP-AllFL/Poly (I:C) produced 
IgG titres of 6.01 ± 0.12 to PvCSP-VK210, 6.06 ± 0.17 to PvCSP-VK247, and 5.66 ± 0.12 to PvCSP-P. vivax-like.
In comparison, after three immunizations with yPvCSP-AllCT/Poly (I:C), IgG titres (log10 ± SEM) were 
6.13 ± 0.06 to PvCSP-VK210, 6.06 ± 0.06 to PvCSP-VK247, and 5.86 ± 0.05 to PvCSP-P. vivax-like. With the adju-
vant Montanide plus yPvCSP-AllCT, the IgG titres (log10 ± SEM) were 5.66 ± 0.09 to PvCSP-VK210, 5.42 ± 0.06 
to PvCSP-VK247, and 5.16 ± 0.09 to PvCSP-P. vivax-like. IgG titres specific to CSP were significantly higher in 
animals vaccinated with Montanide ISA720 than in those that received Poly (I:C) after one boost (P < 0.001). 
However, both formulations were highly immunogenic after two boosts, with a potent humoral response elicited 
in C57BL/6 mice.
To determine the specificity of anti-yPvCSP-AllFL and anti-yPvCSP-AllCT Abs, mouse serum was tested for 
the three individual FliC-PvCSP-repeats. In addition, FliC-MSP119-PADRE was used to exclude the possibil-
ity that Abs cross-react with the FliC region. By ELISA, significant differences were found in antibody titres 
to FliC-PvCSP-VK247 (P < 0.001) (Fig. 3d). After three doses of immunization with yPvCSP-AllFL/Poly (I:C), 
mean IgG titres (log10 ± SEM) were 3.60 ± 0.10 to FliC-PvCSP-VK210, 2.75 ± 0.06 to FliC-PvCSP-VK247, 
and 3.96 ± 0.06 to FliC-PvCSP-P. vivax-like. The formulation yPvCSP-AllCT/Poly (I:C) produced IgG titres of 
3.85 ± 0.25 to FliC-PvCSP-VK210, 2.70 ± 0.20 to FliC-PvCSP-VK247, and 4.26 ± 0.15 to FliC-PvCSP-P. vivax-like. 
In comparison, after three immunizations with yPvCSP-AllFL/Montanide ISA720, IgG titres were 3.96 ± 0.12 to 
Figure 1. Representation of Plasmodium vivax circumsporozoite (CS) proteins expressed from Pichia pastoris. 
(a) Schematic representation of the construction and open reading frame of protein PvCSP-AllFL. (b) PvCSP-
AllCT. Sequence repeats in the variant PvCSP-VK210 are indicated in yellow; PvCSP-P. vivax-like in blue; and 
PvCSP-VK247 in green. (c) Amino acid sequence of the protein yPvCSP-AllFL. (d) Amino acid sequence of the 
protein yPvCSP-AllCT. Hexa-histidine sequences are indicated in blue.
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FliC-PvCSP-VK210, 3.40 ± 0.20 to FliC-PvCSP-VK247, and 3.91 ± 0.12 to FliC-PvCSP-P. vivax-like. With the 
adjuvant Montanide plus yPvCSP-AllCT, the IgG titres were 3.50 ± 0.15 to FliC-PvCSP-VK210, 2.75 ± 0.06 to 
FiC-PvCSP-VK247, and 3.50 ± 0.11 to FliC-PvCSP-P. vivax-like. As expected, animals vaccinated with the above 
formulations did not generate antibodies to FliC-MSP119-PADRE. No significant differences were found in anti-
body titers specific to FliC-CSP in animals vaccinated with Poly (I:C) or Montanide ISA720.
The subclasses of IgG Abs (IgG1, IgG2b, IgG2c, and IgG3) elicited against PvCSP-repeats were measured 
in sera after three doses (Fig. 4). High levels of IgG1 were observed in animals that received yPvCSP-AllFL or 
yPvCSP-AllCT with either adjuvant. A significant predominance of subclass IgG1 Abs (IgG1 > IgG2c, P < 0.001) 
elicited against allelic variants PvCSP-VK210 (Fig. 4a) and P. vivax-like (Fig. 4c) were determined. These results 
indicate a Th2-polarised response.
The affinity of Abs induced to chimeric yPvCSP-AllFL or yPvCSP-AllCT was tested by ELISA using bac-
terial constructions25 in the presence of a denaturing agent (6 M urea). Sera collected after the 3rd dose with 
yPvCSP-AllFL or yPvCSP-AllCT and in the presence of adjuvants Poly (I:C) or Montanide ISA720 were incubated 
with PvCSP variants, in the presence and absence of 6 M urea. Avidity was calculated as percentage of OD492 
Figure 2. Expression, purification, and biophysical analyses of recombinant proteins. (a) SDS-PAGE (12%) 
of yPvCSP-AllFL and yPvCSP-AllCT proteins, stained with Coomassie blue under reducing conditions. (b) 
Immunoblotting analyses of recombinant yPvCSP-AllFL and yPvCSP-AllCT. (1). Anti-histidine tag mAb 
(diluted 1:1,000, GE Healthcare); (2). Anti-PvCSP-VK210 mAb (diluted 1:1,000) 3. Anti-PvCSP-VK247 mAb 
(diluted 1:11,000). NR and R: proteins under non-reducing and reducing conditions (with 2-mercaptoethanol), 
respectively; (c) The purity of proteins yPvCSP-AllFL and yPvCSP-AllCT, after a combination of chromatographic 
separations, was analysed by RP-HPLC. The gradient elution was developed with 0.1% TFA in water and 0.1% 
TFA in 90% acetonitrile at 22 °C, and a rate of 1 mL/min for 30 minutes on a C18 column (Phenomenex). MW: 
molecular weight. (d) The secondary structure of yPvCSP-AllFL and yPvCSP-AllCT was analysed by a circular 
dichroism (CD) spectrum. The CD spectrum of the recombinant proteins was recorded from 190 to 260 nm 
using a JASCO-J815 spectropolarimeter.
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obtained in presence of urea, considering 100% as the OD492 obtained in absence of urea18. The avidity of Abs 
induced in all vaccination protocols ranged between 40 and 60% to PvCSP-VK210, PvCSP-VK247 and PvCSP-P. 
vivax-like (Table 1). MAbs used as control (mAb anti-VK210 and mAb anti-VK247) had a higher avidity, 81.39% 
and 85.05%, induced against the respective inducing proteins PvCSP-VK210 and PvCSP-VK247, demonstrating 
a strong antigen-Ab affinity. In addition, sera from mice immunized with yPvCSP-AllFL or yPvCSP-AllCT in Poly 
(I:C) were able to recognize the native protein sporozoites isolated from Anopheles mosquitoes fed with blood 
from Thailand volunteers infected with P. vivax (Fig. 5).
Homologous and heterologous prime-boost vaccination protected mice against a 
PvCSP-transgenic parasite challenge. In order to analyse the functionality of the anti-PvCS Abs, 
we used two chimeric parasites (Pb/PvVK210 and Pb/PvVK247) to perform challenge studies in a rodent 
malaria model27. Sera from C57BL/6 mice were highly reactive to the homologous proteins, yPvCSP-AllFL or 
yPvCSP-AllCT, after the third dose using protein (PPP) in adjuvant Poly(I:C) (Fig. 6a). In experiments to examine 
protective efficacy of the heterologous prime-boost regimen (AdPP), using prime AdHu5 or AdC68 (Fig. 6d–f), 
we immunized a second mouse strain (BALB/c). We found that mice immunized using PPP (Fig. 6b,c) or AdPP 
(Fig. 6e,f) protocols showed a significant delay in the mean pre-patent period (P < 0.001), relative to the control 
mice injected with Poly(I:C) only. Sterile protection was not induced, however the median time to reach 1% 
of parasitemia was higher in all vaccinated animals than in the control group, in both vaccination regimens 
(Table 2). Animals in the control groups reached 1% parasitemia on day 5 after infection, whereas the vacci-
nated mice presented no parasites in their blood at that time. More relevant, there was a positive correlation 
between levels of IgG and time to reach 1% of parasitemia in all vaccination schedule (PPP regimen versus chal-
lenge with Pb/PvVK210, R = 0.911, Fig. 7a; PPP regimen versus challenge with Pb/PvVK247, R = 0.907, Fig. 7b; 
Figure 3. IgG Ab and specificity responses in immunized mice. Groups of 6- to 8-week-old female C57BL/6 
mice (n = 6) were immunized subcutaneously with 10 µg of each recombinant protein and Poly (I:C) (50 µg/
dose) or Montanide ISA720 (7:3). IgG titres were measured by ELISA against the homologous proteins and 
individual full-length PvCSP variants. (a) PvCSP-VK210. (b) PvCSP-VK247, and (c) PvCSP-P. vivax-like. The 
results are expressed as the arithmetic mean titres of each group (log10 ± SEM), and were compared by one-way 
ANOVA followed by Tukey test for multiple comparisons. Significant differences between groups are denoted 
on the graph as follows: *P < 0.05, **P < 0.01, and ***P < 0.001. Non-significant (ns) differences are indicated 
(P > 0.05). (d) The elicited Abs recognised the different allelic variants and were directed at the central repeats, 
as shown by assays against the repeats fused to flagellin FliC (FliC-PvCSP-repeats) after three doses.
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AdPP regimen versus challenge with Pb/PvVK210, R = 0.972, Fig. 7c; AdPP versus challenge with Pb/PvVK247, 
R = 0.937, Fig. 7d). A positive correlation was also observed when IgG subclasses were analysed (data not shown).
Discussion
Selecting an antigen is one of the crucial steps in developing a vaccine. For a vaccine intended to prevent or delay 
infection caused by malarial parasites, the antigens exposed on the surfaces of sporozoites and liver-stage par-
asites are attractive targets that can be used alone or combined with other antigens. The aims of this study were 
to compare the immunogenicity, avidity, and specific Ab responses in mice of two recombinant proteins based 
on P. vivax CSP and produced in the P. pastoris system. Furthermore, the protective efficacy of these vaccine 
Figure 4. Ratio of IgG1/IgG2c to yPvCSP-AllFL and yPvCSP-AllCT after the immunization schedule. Chimeric 
proteins yPvCSP-AllFL and yPvCSP-AllCT induced Th2-polarised Abs in C57BL/6 mice. (a) FliC-PvCSP-VK210, 
(b) FliC-PvCSP-VK247, and c. FliC-PvCSP-P. vivax-like. The results are expressed as the arithmetic mean 
titres of each group (log10 ± SEM) and were compared by one-way ANOVA followed by Tukey test for multiple 
comparisons. Significant differences between groups are denoted on the graph as follows: *P < 0.05, **P < 0.01, 
and ***P < 0.001. Non-significant (ns) differences are also indicated (P > 0.05).
Antibody Protein % Avidity [Poly (I:C)] % Avidity [Montanide ISA720] % Avidity
anti-yPvCSP-AllFL*
PvCSP-VK210 42.70 ± 1.04 46.41 ± 6.20 —
PvCSP-VK247 42.04 ± 8.12 48.29 ± 7.54
PvCSP-P. vivax-like 53.14 ± 6.76 55.50 ± 7.15
anti-yPvCSP-AllCT*
PvCSP-VK210 55.89 ± 9.06 49.64 ± 6.72 —
PvCSP-VK247 58.33 ± 14.17 58.01 ± 14.01
PvCSP-P. vivax-like 46.22 ± 11.93 48.34 ± 7.94
mAb anti-VK210 PvCSP-VK210 — — 81.39 ± 1.57
mAb anti-VK247 PvCSP-VK247 — — 85.05 ± 2.58
Table 1. Comparative analysis of Ab avidity. *No significant differences were found between the % avidity 
analysed (One way ANOVA by Tukey’s post-test).
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formulations using homologous and heterologous immunization regimens was evaluated in a murine model, in 
which immunized mice were challenged with transgenic P. berghei-P. vivax sporozoites.
The humoral immune response is crucial to block initial infection of the mammalian host by malarial sporo-
zoites3. In previous works, we showed that recombinant proteins based on the P. vivax CS protein were able to 
generate high Ab titres in mice, demonstrating their immunogenic potential23–25. However, the production and 
purification processes of such bacterial-produced proteins was a step to be improved; as they were recovered from 
insoluble fractions and an urea treatment was required to obtain the recombinants. Based on these results, we 
decided to express recombinant PvCS proteins in P. pastoris eukaryotic system, which has been successfully and 
reproducibly utilised in our previous studies28,29. Thus, two fusion-proteins were used in this study: yPvCSP-AllCT 
and yPvCSP-AllFL. The first construct was formulated based on the CSP portion of the RTS,S vaccine4 and is a 
mix of the three repeat sequences (VK210, VK247, and P. vivax-like) with the C-terminal region of PvCSP30. As 
for yPvCSP-AllFL, this recombinant includes also the PvCSP N-terminal region, since humans immunized with 
vaccine formulations containing long synthetic peptides representing portions of the N and C terminal of PvCSP 
generated Abs that inhibited the invasion of sporozoites in vitro31 and the N-terminal region of P. falciparum CSP 
was proposed to be a target for inducing protection in vaccine formulations32.
Our first objective was to produce both proteins in order to compare their immunogenicity in formulations 
with suitable adjuvants. The recombinants were obtained with a high degree of purity and with proper secondary 
conformation upon expression in P. pastoris system and chromatographic purification. In addition, they were 
Figure 5. Indirect immunofluorescence analysis using sera from C57BL/6 mice. Microscope slides containing 
fixed spz of P. vivax obtained from patients from Thailand were incubated with pools of sera from mice 
immunized with yPvCSP-All in the presence of Poly (I:C). (a) Polyclonal sera anti-yPvCSP-AllFL (1:50). (b) 
Polyclonal sera anti-yPvCSP-AllCT (1:50). (c) sera from mice immunized with PBS in adjuvant (1:50). (d) mAb 
anti-VK210 (1:50). The white bars are equivalent to 10 micrometers (10 µm).
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confirmed to be specific for variants PvCSP-VK210 and PvCSP-VK247 by immunoblotting using mAbs. The 
recombinant antigens induced high titres of IgG Abs specific for the three P. vivax CSP variants (VK210, VK247, 
and P. vivax-like) in C57BL/6 mice when administered with either adjuvant Poly (I:C) or Montanide ISA720. 
High Ab titres using Montanide ISA720 have been reported previously33,34 and Poly (I:C) was also demonstrated 
to be a very potent adjuvant when administered together with malaria antigens25,35,36. Thus, immunization with 
the recombinant proteins described herein was able to generate high titres of Abs that should recognise each nat-
ural genetic variant of P. vivax. Interestingly, immunization with either yPvCSP-AllCT or yPvCSP-AllFL emulsified 
in adjuvant Montanide ISA720 generated IgG Abs reaching a peak in the response after the second dose, whereas 
in the presence of adjuvant Poly (I:C), a third dose was required to elicit Ab titres of the same magnitude. The 
precise reason for this difference is not clear, and to our knowledge this is the first report of a comparison between 
these adjuvants, regarding antibody production.
In spite of these differences after the second dose, there were not significant differences in titres after the 
third dose. We were interested then in assessing the specificity and avidity of these Abs. The specificity of 
anti-yPvCSP-AllCT and anti-yPvCSP-AllFL Abs was evaluated using constructs with only the repeats of each 
PvCSP variant fused to flagellin (FliC) from Salmonella enterica serovar Typhimurium23,24. Immunized mice 
generated high titres of IgG Ab directed against PvCSP repeats, primarily directed at VK210 and P. vivax-like var-
iants. Our results are in agreement with those demonstrated for the VMP001 formulation; an effective immune 
response against P vivax should not necessarily be associated with a high number of repeats13. High titres of Abs 
towards the No Repeats protein (N- and C-terminal domains only) were also elicited using both adjuvants. The 
Figure 6. IgG Ab response in immunized mice, and blood-stage parasitemia with the homologous and 
heterologous prime-boost regimens. In the homologous prime-boost regimen (PPP), groups of 6- to 8-week-
old female C57BL/6 mice were immunized subcutaneously (s.c.) with 10 µg of each recombinant protein and 
Poly (I:C) (50 µg/dose). In the heterologous prime-boost regimen (AdPP), groups of 6- to 8-week-old female 
BALB/c mice were immunized intramuscularly (i.m.) with AdHu5 or AdC68 at a dose of 108 infection units, 
and boosted twice with 10 µg of each recombinant protein and Poly (I:C) (50 µg/dose). Twenty-one days after 
third dose, mice were challenged with 2,000 Pb/PvVK210 spz. or with 2,000 Pb/PvVK247 spz, alternatively. 
Protection is indicated by the time predicted to reach 1% blood-stage parasitemia using a linear regression 
model. Blood-stage parasitemia was monitored from day 3 post-challenge until mice reach 1% parasitemia. 
Titres of IgG Abs against yPvCSP-AllCT and yPvCSP-AllFL were measured by ELISA. Serum was collected after 
the third dose. (a) and (d). IgG Ab titres of the immunized mice using a homologous (PPP) or heterologous 
prime-boost regimen (AdPP), respectively. (b) and (c). Time to 1% blood-stage parasitemia post-challenge with 
Pb/PvVK210 spz (n = 6 per group) or Pb/PvVK247 spz (n = 6 per group) after PPP regimen. (e) and (f). Time 
to 1% blood-stage parasitemia post-challenge with Pb/PvVK210 spz (n = 6 per group) or Pb/PvVK247 spz 
(n = 6 per group) after AdPP regimen. For IgG Ab titre, two independent assays were performed. The results are 
expressed as the arithmetic mean titres of each group (log10 ± SEM) and were compared by one-way ANOVA 
followed by Tukey’s Multiple Comparison Test. Significant differences between groups are denoted on the graph: 
***P < 0.001 and for time to reach 1% of parasitemia, two independent assays were performed. Significant 
value of ***P < 0.001 was determined by one-way ANOVA with Mantel-Cox test.
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exact effect of the production of Abs to each PvCSP region on the protection remains unclear so far, and the 
practical implications of these differences will only be elucidated in a human challenge model. However, if the 
humoral response plays a major role in protection, such chimeric CSP proteins could generate Abs able to recog-
nise and neutralise sporozoites of all the three allelic variants of P. vivax.
The avidity percentage measured in a polyclonal sera indicates the proportion of the antibodies which are able 
to bind strongly to their antigens; as the chaotropic agent used in this assay disrupts weakly bound antibodies18. 
Although the avidity levels of elicited Abs cannot be considered high in relation to mAbs, the fact of 42–58% of 
elicited Abs being resistant to the denaturing action of 6 M urea indicates a high avidity of the antigen-Ab bonds 
of at least 42% of elicited Abs. Moreover, Moon et al. (2012) demonstrated that the same avidity level of Ab 
towards pathogen-mimicking nanoparticle vaccines (VMP001-NPs) was high enough to agglutinate live P. vivax 
sporozoites, indicating their potential as effector antibodies37.
The predominant IgG1 Ab response (IgG1/IgG2c ratio >1) found in sera of immunized mice is believed to be 
related to the stimulation of Th2 cells, which assist in the stimulation of Th1 cells38. This predominance of IgG1 
was also observed in previous studies by our group, via analysis of sera from mice that were immunized with 
vaccine formulations containing the recombinant PvCSP fused to FliC23,24.
As no statistical differences regarding specificity, avidity or IgG subclasses distribution were observed between 
antibodies elicited by vaccine formulations containing either adjuvant; we decided to move forward with only one 
adjuvant. Poly (I:C) has been previously used in several vaccination protocols with PvCSP-based proteins25 and 
the stimulation pathway is already known both in humans and mice. This double-stranded RNA acts by stimu-
lating TLR3 present in antigen-presenting cells that induce signaling through multiple inflammatory pathways, 
including NF-κB39,40. On the contrary, the pathway of stimulation for Montanide ISA720 is not yet known, mak-
ing it difficult to make a major investment in its use in vaccines. Thus, we opted for the use of Poly (I:C) due to the 
better knowledge about this adjuvant, both regarding antibody response as well as signaling pathway.
We had previously demonstrated that the heterologous prime-boost regimen, using AdC68-PvCSP or 
AdHu5-PvCSP for priming and recombinant proteins for boost (AdPP), was as good as the homologous regimen 
in generating high IgG Ab titres specific for PvCSP antigen25. In this study, we confirmed those findings by using 
yeast-produced instead of bacteria-produced recombinant proteins, and we tested for the first time the protec-
tive efficacy of these adenoviruses applied in the AdPP regimen. The reason for using both the Human 5 and 
the Chimpanzee 68 serotypes (AdHu5-PvCSP and AdC68-PvCSP respectively) in our immunization schedules 
relies in some concerns related to the use of Human 5 serotype adenovirus as vaccine carriers. Infections with this 
serotype are frequent in the early life of a significant percentage of the population, and the consequences of the 
presence of antibodies towards these adenoviruses in pre-immunized subjects are not completely known, both 
regarding vaccine potency and safety concerns. For these reasons, Simian serotypes as AdC68 are very attractive 
options41,42. However, as the immune response in humans towards AdHu5 is more potent and has been more 
deeply studied than the AdCh68 serotype, we decided to analyse the protective efficacy of both adenoviruses 
carrying the PvCSP sequence.
Under our experimental conditions, no significant differences in terms of immunogenicity or protective effi-
cacy were observed among the different formulations and regimens utilized. Since both recombinant proteins 
under test (yPvCSP-AllFL and yPvCSP-AllCT) combined with suitable adjuvants were able to generate high Ab 
Challenge 
(2,000 spz) Vaccine Regimen
Mouse 
Strain
Median Survival 
(Days)
Mean ± Standard 
Error (SEM) Limits
Pb/PvVK210
Naive
C57BL/6
4.89 4.84 ± 0.10 4.22–5.39
Poly (I:C) 5.03 5.10 ± 0.10*** 4.73–5.92
PPP (yPvCSP-AllCT) 9.17 9.26 ± 0.16*** 8.20–9.80
PPP yPvCSP-AllFL) 9.45 9.36 ± 0.14*** 8.62–9.92
Pb/PvVK247
Naive
C57BL/6
4.48 4.66 ± 0.13 4.01–5.24
Poly (I:C) 4.92 4.96 ± 0.16*** 4.25–5.82
PPP (yPvCSP-AllCT) 8.96 9.03 ± 0.12*** 8.39–9.73
PPP (yPvCSP-AllFL) 8.94 9.03 ± 0.18*** 8.16–10.64
Pb/PvVK210
Naive
BALB/c
5.10 4.96 ± 0.12 4.07–5.56
AdPP (AdHu5 + yPvCSP-AllCT) 9.27 9.37 ± 0.14*** 8.89–10.51
AdPP (AdHu5 + yPvCSP-AllFL) 9.48 9.55 ± 0.16*** 8.88–10.52
AdPP (AdC68 + yPvCSP-AllCT) 9.20 9.53 ± 0.24*** 8.92–11.90
AdPP (AdC68 + yPvCSP-AllFL) 9.12 9.44 ± 0.17*** 8.78–10.63
Pb/PvVK247
Naive
BALB/c
5.05 5.21 ± 0.13 4.67–5.97
AdPP (AdHu5 + yPvCSP-AllCT) 9.26 9.62 ± 0.21*** 8.92–10.95
AdPP (AdHu5 + yPvCSP-AllFL) 9.52 9.68 ± 0.18*** 8.99–10.73
AdPP (AdC68 + yPvCSP-AllCT) 9.54 9.73 ± 0.18*** 9.08–10.27
AdPP (AdC68 + yPvCSP-AllFL) 9.17 9.63 ± 0.35*** 8.72–12.37
Table 2. Summary of the efficacy induced by the homologous and heterologous vaccination regimens. 
Significant differences compared to naïve group are denoted on the table (***P < 0.001 in all cases, One way 
ANOVA).
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titers targeting all their different domains in equal proportion, and more important, their protective effect against 
Pb/Pv sporozoite challenge was also similar, we cannot exclude either of them as vaccine candidates for clinical 
trials. As for the use of adenovirus for heterologous (AdPP) compared with homologous (PPP) prime-boost reg-
imens, a significant delay in the time to reach 1% parasitemia was seen in 100% of the mice vaccinated with both 
immunization regimens. Therefore, due to the absence of advantages using the more complex AdPP system, we 
suggest that the homologous PPP regime would be attractive for clinical trials. It is important to highlight that for 
malaria sporozoite challenges, a time delay in reaching the liver is an important step in determining protection 
against liver-stage parasites16. A comparable time delay for parasitemia was observed in 59% of individuals vacci-
nated against P. vivax with the vaccine candidate VMP001/AS01B15. Even if these vaccination approaches did not 
induce sterile protection, a significant delay in parasitemia is an important advance, taking into account that a P. 
vivax vaccine with low to moderate effectiveness against infection could hypothetically decrease parasite relapses 
and thus reduce malaria transmission43. In addition, these results would pave the way for approaches to improve 
strategies for new vaccine formulations.
The results presented in this study support the hypothesis that CSP-based vaccine formulations can induce 
immunity and protection against the two major PvCSP, VK210 and VK247 alleles. As our proposed formulations 
cover constructs representing the three allelic variants of PvCSP, they may serve as the basis for a universal vac-
cine against malaria caused by P. vivax.
Methods
Gene design and construction of the recombinant proteins. Both CSP-based recombinant proteins 
used in this study contained immunodominant regions comprising core amino acid repeats from different P. 
vivax alleles (VK210, VK247, and P. vivax-like). Although one CSP recombinant contained the N- and C-terminal 
regions (yPvCSP-AllFL), another lacked the N-terminal region (yPvCSP-AllCT). The gene design, construction 
and expression in P. pastoris of yPvCSP-AllCT was recently described30. As for yPvCSP-AllFL, a synthetic gene 
codon-optimised for expression in P. pastoris yeast was obtained commercially (GenScript USA Inc., Piscataway, 
NJ). The chimeric protein presented six copies of the repeat sequence in the classic allele VK210 (GDRA[A/D]
GQPA) in their central region, followed by six copies of the repeat in the P. vivax-like allele (APGANQEGGAA), 
and five copies of the repeat in the VK247 allele (ANGAGNQPG). These tandem repeat sequences were followed 
by the N- and C-terminal portion identical to that in P. vivax CSP Salvador I strain sequence. Hexa-histidine 
(His6)-coding sequences were added at the 3′- and 5′-ends of the synthetic CSP gene immediately after and 
before sites of the restriction enzymes EcoRI and NotI (New England Biolabs USA Inc., Ipswich, MA) to enable 
Figure 7. Correlation between titres of IgG Abs pre-challenge against yPvCSP-All and parasitemia post-
challenge. Mice were immunized and challenged as described in the legend of Fig. 6. (a) and (b). C57BL/6 mice 
were challenged with Pb/PvVK210 spz or Pb/PvVK247 spz, respectively, after PPP regimen. (c) and (d). BALB/c 
mice were challenged with Pb/PvVK210 spz or Pb/PvVK247 spz, respectively, after AdPP regimen. Correlation 
coefficient analyses were determined with a Pearson bivariate, two-tailed test of significance (GraphPad Prism).
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purification. The gene was sub-cloned into vector pPIC9K (Invitrogen, Life Technologies Corporation USA Inc., 
Waltham, MA), which contains a signal peptide (α-factor) for secreted expression (Invitrogen). Figure 1c,d shows 
the amino acid sequences of yPvCSP-AllFL and yPvCSP-AllCT proteins.
Expression and purification of yPvCSP-AllFL. Similarly to that described for yPvCSP-AllCT30, the plas-
mid pPIC9K-pvcsallFL was linearized with SalI to transform the P. pastoris GS115 strain (his4−) by electroporation 
following the manufacturer’s recommendations (Invitrogen). Approximately 50 His+clones transformed with 
pPIC9K-pvcsallFL were screened for high-copy-number integration by G418 selection. Based on an immunoblot-
ting analysis with mouse monoclonal anti-PvCSP-VK210 (2F2) and anti-PvCSP-VK247 (2E10.9)26, clones with 
Mut+ phenotype secreting high levels of yPvCSP-AllFL were selected. The recombinant proteins were expressed 
and purified as previously described by our group28.
Characterisation of yPvCSP-AllFL and yPvCSP-AllCT. The recombinant proteins were characterised 
using a 12% sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-PAGE) gel stained with Coomassie 
blue, immunoblotting, reverse-phase chromatography (RP-HPLC), and circular dichroism spectroscopy. Protein 
expression was confirmed by western blotting. For this analysis, the protein fractions were transferred from a 
12% SDS-PAGE gel to a nitrocellulose membrane and exposed to mAbs [anti-His tag, 1:1,000, GE Healthcare; 
anti-PvCSP-VK210 (2F2), 1:1,000; and anti-PvCSP-VK247 (2E10.E9), 1:1,000 26, followed by anti-mouse horse-
radish peroxidase (HRP)-conjugated IgG Ab (KPL). The bands were visualised using an ECL Western Blotting 
Analysis System (GE Healthcare).
The high yield and purity of the recombinant proteins were confirmed by RP-HPLC using a Phenomenex 
Jupiter C18 column (4.6 mm × 250 mm, 5 µm particle, and 300 Å pore) with a Shimadzu Prominence HPLC 
System Solution (Shimadzu JPN Corp., Kyoto, KY). The HPLC procedure was performed using a 90% acetoni-
trile gradient in 0.1% trifluoroacetic acid at room temperature (RT, 22 °C) at a flow rate 1 mL/min for 30 min. A 
UV-visible absorbance detector (DAD: diode array detector, Shimadzu SPD M20A) was used for detection at 
214 nm as described44.
The secondary structure of the recombinant proteins was analysed by circular dichroism (CD), using a 
JASCO-J815 spectropolarimeter (Jasco, Tokyo, Japan) at 25 °C. The purified proteins (diluted to 10 µM in phos-
phate buffered saline (PBS)) were loaded into a 5-mm quartz cuvette. Far-UV measurements (four scans) were 
obtained at wavelengths of 250–190 nm at 0.1-nm intervals, with a 1-nm bandwidth and 1 s response time. The 
spectrum presented is the average of the four scans, and the data obtained are reported as values of molar elliptic-
ity [θ]MRW (deg × cm2 × dmol-1). A baseline measurement with PBS was subtracted from each protein spectrum. 
The data were smoothed with a Savitzky-Golay filter, and the percentages of secondary structure were predicted 
using the CD Analysis and Plotting Tool (http://capito.nmr.leibniz-fli.de/index.php).
Recombinant proteins expressed in E. coli. Previously, we described the generation of three recom-
binant proteins representing each PvCSP variant (VK210, VK247, and P. vivax-like; constructs with the 
N- and C- terminal portions25), FliC-MSP119-PADRE (non-related protein containing FliC45), and the three 
FliC-PvCS-repeats (FliC-PvCSP-VK210, FliC-PvCSP-VK247, and FliC-PvCSP-P. vivax-like; constructs without 
the N- and C-terminal portions23,24).
Adenoviral vectored vaccines. Recombinant replication-defective human adenovirus serotype 5 (AdHu5) 
and chimpanzee adenovirus serotype (AdC68) vectors with the sequence Ad-PvCSP (containing the three-repeat 
variants plus N- and C-terminal regions in fusion) were generated previously25. These adenoviruses were ampli-
fied in HEK 293 cells; purification, quality control, and quantification were performed as described46. The adeno-
viruses were used in the heterologous prime-boost vaccination regimen.
Mouse immunizations. Homologous prime-boost regimen (PPP) in two adjuvants for comparative studies. 
Groups of six female C57BL/6 (H-2b) inbred mice (n = 6/group) aged 6–8 weeks (Harlan, UK) were used in all 
experiments. Immunizations were performed by subcutaneous (s.c.) administration of 10 µg of the chimeric pro-
tein in presence of the adjuvant Poly (I:C) (HMW, 50 µg/ dose; Invivogen) or Montanide ISA720 (7:3), SEPPIC], 
three times at 21-day intervals. The controls received only PBS emulsified in the adjuvant. Twenty-one days after 
each immunization, blood was collected from tails, and sera were stored at −20 °C until use.
Homologous (PPP) and heterologous (AdPP) prime-boost regimens in an experimental challenge. Mice were 
exposed to the homologous prime-boost vaccination regimen (PPP) after anesthetising using an inhalation cham-
ber containing a mix of isoflurane (23.5%) and oxygen (12 L/min). Mice were immunized (s.c.) three times at 
2-week intervals, with a 100 μL dose containing sterile PBS and 10 μg/dose of recombinant protein (yPvCSP-AllCT 
or yPvCSP-AllFL) with 50 μg/dose of Poly (I:C) HMW adjuvant (Invivogen). One control group received only PBS 
with 50 μg/dose of Poly (I:C). A naïve group was also used as a control.
For the other arm, the AdPP vaccination regimen was administered to female BALB/c (H-2d) mice 6–8 weeks 
of age purchased from Harlan/UK. Mice were immunized three times at 2-week intervals. Mice were primed 
with AdHu5 or AdC68 at a dose of 108 infectious units (IU), administered intramuscularly (i.m.) into the tibialis 
anterior, with 25 μL in each leg, for a final volume of 50 μL per mouse. Later, the mice were boosted twice using 
the recombinant protein formulations described above. Fifteen days after each immunization, blood was collected 
from tails, and sera were stored at −20 °C until use.
Detection of Ab titres to each PvCSP variant. Collected sera were analysed for the presence of Abs against 
the recombinant proteins described above. Abs to the PvCSP variants (VK210, VK247, and P. vivax-like), 
www.nature.com/scientificreports/
1 2SCIeNTIfIC REPORTS |  (2018) 8:1118  | DOI:10.1038/s41598-017-19063-6
FliC-MSP119-PADRE (non-related protein containing FliC), and the three FliC-PvCSP-repeats in mice sera 
were detected by ELISA on days 21, 42, and 63, as previously described45. The same protocol was used to detect 
Abs against yPvCSP-AllFL and yPvCSP-AllCT in sera from mice exposed to homologous and heterologous prime 
boost-regimens on days 15, 30, and 45 after priming and 4 days after challenge. The specific titres were considered 
the highest dilution yielding an OD492 greater than 0.1. The results were expressed as means of IgG titres (log10)/
SEM. The avidity of IgG Abs was determined using an extra step of incubation with 6 M urea for 5 min. The 
percentage was defined as avidity (OD492/630 with treatment)/(OD492/630 untreated) × 100%18,37. As controls, mAb 
anti-VK210 [1: 500]) and anti-VK247 [1: 500] were used.
P. vivax slide preparation and indirect immunofluorescence assay. Anopheles cracens mosquitoes were fed on 
human blood obtained from infected Thai patients using a membrane-based feeder system47. Blood sample col-
lection from malaria patients was performed in accordance with the relevant guidelines and regulations and 
was approved by Oxford Tropical Research Ethics Committee (Reference 28-09). After two weeks, aseptically 
dissected infected salivary glands were disrupted in a glass tissue grinder and the sporozoite preparation was 
deposited on glass slides. Slides were dried at room temperature and kept frozen at -20C before use. The glass 
slides were fixed with metanol for 10 min and blocked with BSA 5% in PBS for 30 min. Sera from C57BL/6 mice 
immunized with yPvCSP-AllFL or yPvCSP-AllCT in the presence Poly (I:C) (dilution 1:50) were applied to the 
slides and incubated for 1 h. The slides were then washed 3 times with PBS before the addition of anti-mouse 
IgG conjugated to Alexa Fluor 568 (Molecular Probes) diluted 1:500 with 5% BSA in PBS. After washed 3 times 
with PBS the cells were stained with DAPI (2 μg/mL). The images were acquired on a DMI6000B/AF6000 (Leica 
Systems) fluorescence microscope coupled to a digital camera system (DFC 365 FX). As a positive control, was 
used the monoclonal antibody anti-VK210 (1:50).
Parasite preparation and experimental challenge. P. berghei ANKA transgenic parasite line 2196cl01 expressing 
PvCSP-VK210 (Pb/PvVK210) and line 2199cl1 VK247 (Pb/PvVK247) sporozoites (spz) used for challenge were 
produced at the Jenner Institute insectary, Oxford University27. Donor mice were infected by intraperitoneal (i.p.) 
injection of cryopreserved infected blood stocks. Exflagellation was first confirmed and Anopheles stephensi mos-
quitoes were exposed to anesthetised infected donor mice for 10 min. After 21 days in a humidified incubator at 
19–21 °C and on a 12-h day-night cycle and fed fructose–p-aminobenzoic acid (PABA) solution, the mosquitoes 
were hand-dissected, salivary glands were isolated, and sporozoites were extracted and resuspended in Schneider’s 
media (Pan Biotech). The total number of sporozoites was determined using a haemocytometer. Experimental chal-
lenges were performed intravenously using 2,000 freshly isolated sporozoites at day 21 after the last immunization.
Thin blood smears to assess parasitemia. Thin blood smears were prepared daily, from day 3 after infection until 
the mice reached 1% parasitemia. The smears were prepared on glass slides with a drop of blood obtained from a 
tail clip. The blood smear was allowed to air-dry before fixation with methanol and staining for at least 15 minutes 
using 10% Giemsa diluted in distilled H2O. The slides were then allowed to air dry at room temperature. Using a 
light microscope, parasitemia was quantified as the percentage of infected erythrocytes in at least 1,000 RBCs per 
mouse. To determine the time required to reach 1% blood-stage parasitemia, a linear regression model was used, 
as previously described16. The time to reach 1% parasitemia was used in survival analyses to assess vaccine efficacy.
Statistical analysis. All analyses were performed using GraphPad Prism version 5.0 (GraphPad Software 
Inc., La Jolla, CA, USA) and graphics were plotted using SigmaPlot version 11.0 (GraphPad Software, La Jolla, 
CA, USA). A comparison of Ab titers in independent samples was performed by one-way analysis of variance 
(ANOVA). One-way ANOVA was also used to compare normally distributed log-transformed means for the 
different animal groups. Multiple comparisons were assessed by Tukey’s post-test with a significance level of 
P < 0.05. The significance in survival curves was determined using a log-rank Mantel-Cox test with a signifi-
cance level of P < 0.05. Correlation coefficient analyses were determined with Pearson bivariate, two-tailed test 
of significance.
Ethics statement. This study was performed in strict accordance with the recommendations of the Guide for the 
Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (http://www.
cobea.org.br/). The protocol (CEUA/FCF no. 475/2014) was approved by the Research Committee on Animal 
Experimentation of the School of Pharmaceutical Sciences of the University of São Paulo, Brazil. All animals and 
procedures for the homologous and heterologous assays performed at the Jenner Institute were conducted in 
accordance with the terms of the UK Home Office Animals Act Project License. Procedures were approved by the 
University of Oxford Animal Care and Ethical Review Committee (PPL30/2889).
The blood samples were collected from malaria patients infected by P. vivax (Mae Sot region, Thailand). All 
patients here used signed an informed consent form after receiving detailed information regarding the study’s 
goals. The study was approved by Oxford Tropical Research Ethics Committee (reference OX28-09).
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